WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated.
The Accelerating Medicines Partnership — an initiative of NIH, several non-profit disease foundations, 10 biopharmaceutical companies and PhRMA — aims to transform the current model for developing new diagnostics and treatments by joining forces to identify and validate promising biological targets of disease.
AMP represents a new, integrated approach to treatment discovery and seeks to increase the number of new diagnostics and therapies for patients while reducing the time and cost associated with their development. The initiative will begin with three- to five-year pilot projects focused on three disease areas: Alzheimer’s, Type 2 diabetes and autoimmune disorders, including rheumatoid arthritis and lupus. AMP data and analyses will be publicly accessible to the biomedical community.